Clicky

Cel-Sci Corporation(CVM) News

Date Title
Oct 1 CEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine® in Head and Neck Cancer
Sep 4 The UK’s Medicines & Healthcare Products Regulatory Agency Grants CEL-SCI a Pediatric Waiver, Bringing Multikine® One Step Closer to Future Marketing Clearance
Aug 15 CEL-SCI Corporation Reports Third Quarter Fiscal 2024 Financial Results
Aug 15 Cel-Sci: Fiscal Q3 Earnings Snapshot
Jul 29 CEL-SCI Announces Closing of $10.8 Million Offering
Jul 26 CEL-SCI Announces Pricing of $10.8 Million Offering
Jul 26 CEL-SCI’s Phase 3 Population Analysis for Upcoming Confirmatory Registration Study in Head & Neck Cancer Demonstrates Well Balanced Patient Population, Confidence in Clinical Results
Jun 18 CEL-SCI Presents Head & Neck Cancer Data at Iddst Annual Congress in Budapest: Risk of Death Cut in Half for Patients Treated With Multikine in the Target Population
May 8 CEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck Cancer
Apr 23 CEL-SCI Appoints Mario Gobbo to Its Board of Directors
Apr 15 CVM: Parallel Engagement on Four Fronts
Mar 19 CEL-SCI’s LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology
Mar 6 CEL-SCI Corporation Issues Letter to Shareholders
Dec 22 CEL-SCI Reports Fiscal 2023 Financial Results and Clinical & Corporate Developments
Dec 8 CVM: NICE To Have Your Support
Dec 4 UK’S National Institute for Health and Care Excellence (NICE) Selects CEL-SCI’s Multikine as Potential New Standard of Care for Head & Neck Cancer
Nov 20 CEL-SCI Announces Closing of $5 Million Public Offering of Common Stock
Nov 16 CEL-SCI Announces Pricing of $5 Million Offering of Common Stock
Aug 11 CEL-SCI Corporation Reports Third Quarter Fiscal 2023 Financial Results
Apr 28 CEL-SCI Announces $1.35 Million Underwritten Confidentially Marketed Public Offering of Common Stock